Magenta Therapeutics, Inc. (MGTA): Price and Financial Metrics

Magenta Therapeutics, Inc. (MGTA): $0.79

0.02 (+3.14%)

POWR Rating

Component Grades













MGTA Stock Price Chart Interactive Chart >

Price chart for MGTA

MGTA Price/Volume Stats

Current price $0.79 52-week high $3.49
Prev. close $0.77 52-week low $0.32
Day low $0.76 Volume 274,900
Day high $0.80 Avg. volume 1,658,279
50-day MA $0.74 Dividend yield N/A
200-day MA $1.18 Market Cap 48.19M

Magenta Therapeutics, Inc. (MGTA) Company Bio

Magenta Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was founded in 2015 and is based in Cambridge, Massachusetts.

MGTA Latest News Stream

Event/Time News Detail
Loading, please wait...

MGTA Latest Social Stream

Loading social stream, please wait...

View Full MGTA Social Stream

Latest MGTA News From Around the Web

Below are the latest news stories about MAGENTA THERAPEUTICS INC that investors may wish to consider to help them evaluate MGTA as an investment opportunity.

Magenta adopts stockholder rights plan to ward off unwanted bids

  • Magenta Therapeutics (NASDAQ:MGTA) announced a stockholder rights plan for one year on Friday in an attempt to reduce the likelihood of unwanted bids for the company ownership.
  • Per the terms, if a party secures 10% or more of beneficial ownership in Magenta (MGTA) common stock or in the event of a merger or similar change in its control, the right holder will be entitled to additional MGTA shares or the shares of the acquirer.
  • ...

    Seeking Alpha | March 31, 2023

Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect t

Yahoo | March 31, 2023

The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics

Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics are included in this Analyst Blog.

Yahoo | March 31, 2023

Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | March 27, 2023

On eve of shutdown, Cambridge biotech loses 84% of staff, including 5 execs

In the midst of exploring a sale, Magenta Therapeutics Inc. is laying off the vast majority of its staff, including five executives.

Yahoo | February 9, 2023

Read More 'MGTA' Stories Here

MGTA Price Returns

1-mo -1.25%
3-mo 100.00%
6-mo -42.75%
1-year -73.49%
3-year -87.40%
5-year N/A
YTD 100.00%
2022 -91.08%
2021 -43.49%
2020 -48.28%
2019 165.96%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8022 seconds.